![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://xbrane.com/en/mfn_news/xbrane-successfully-scales-up-xdivane-biosimilar-candidate-to-opdivo-and-run-an-active-partnering-process/
https://endpts.com/iteos-to-raise-120m-xbrane-and-stada-to-out-license-lucentis-biosimilar/
https://xbrane.com/en/mfn_news/xbrane-provides-regulatory-update-on-fda-review-of-its-ranibizumab-biosimilar-candidate/
https://www.pharmatimes.com/news/stada_and_xbrane_gain_eu_approval_for_biosimilar_ximluci_1480676
https://www.stada.com/blog/posts/2022/september/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci
https://www.centerforbiosimilars.com/view/biosimilar-business-news-roundup-russia-launches-omalizumab-remsima-sales-soar-xbrane-trial-results
https://www.globenewswire.com/news-release/2022/02/07/2380345/0/en/Biogen-and-Xbrane-Announce-Commercialization-and-License-Agreement-for-Proposed-Biosimilar-Referencing-CIMZIA-Certolizumab-pegol-with-the-Potential-to-Treat-Rheumatoid-Arthritis.html
https://xbrane.com/en/mfn_news_en/xbrane-has-initiated-development-of-two-new-biosimilar-candidates-building-an-oncology-biosimilar-portfolio-targeting-e23-billion-in-annual-reference-product-sales/